AstraZeneca Lynparza supplemental application gets US priority review
AstraZeneca
11,780.00p
16:45 20/09/24
-0.99%
-118.00p
AstraZeneca said that its Lynparza breast cancer drug's supplemental new application had been accepted and granted Priority Review by the US Food and Drug Administration.
FTSE 100
8,229.99
17:14 20/09/24
n/a
n/a
FTSE 350
4,543.89
16:49 20/09/24
n/a
n/a
FTSE All-Share
4,501.08
17:04 20/09/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,415.97
16:49 20/09/24
-1.31%
-296.71
Lynparza is used to treat patients with early breast cancer who have already received chemotherapy either before or after surgery, the company said on Tuesday.
The Anglo-Swedish added the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.